Ebola viral load at diagnosis associates with patient outcome and outbreak evolution

Journal of Clinical Investigation

Volumn 125, Issue 12, 2015, Pages 4421-4428

  De La Vega, Marc Antoine ^a,b   Caleo, Grazia ^c   Audet, Jonathan ^a,b   Qiu, Xiangguo ^a,b   Kozak, Robert A ^a   Brooks, James I ^d   Kern, Steven ^e   Wolz, Anja ^f   Sprecher, Armand ^f   Greig, Jane ^c   Lokuge, Kamalini ^g   Kargbo, David K ^h   Kargbo, Brima ^h   Di Caro, Antonino ⁱ   Grolla, Allen ^a   Kobasa, Darwyn ^a   Strong, James E ^a   Ippolito, Giuseppe ⁱ   Van Herp, Michel ^f   Kobinger, Gary P ^a,b,j  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

^f MSF   (Belgium)

^g Australian National University College of Health and Medicine   (Australia)

^h Ministry of Health (MoH) and Sanitation   (Sierra Leone)

ⁱ NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS LOAD; BIOLOGICAL MODEL; BLOOD; SIERRA LEONE;

ANTIBODIES, VIRAL; DISEASE OUTBREAKS; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOGLOBULIN G; MALE; MODELS, BIOLOGICAL; SIERRA LEONE; VIRAL LOAD;

EID: 84948807329     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83162     Document Type: Article

References (21)

1. Kuhn JH, et al. Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Viruses. 2014;6(9):3663-3682.
2. Kuhn JH, Jahrling PB. Clarification and guidance on the proper usage of virus and virus species names. Arch Virol. 2010;155(4):445-453.
3. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849-862.
4. Ansari AA. Clinical features and pathobiology of Ebolavirus infection. J Autoimmun. 2014;55:1-9.
5. Baize S, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014;371(15):1418-1425.
6. Dudas G, Rambaut A. Phylogenetic analysis of Guinea 2014 EBOV Ebolavirus outbreak. PLoS Curr. 2014;6.
7. Gire SK, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345(6202):1369-1372.
8. Ebola virus disease in Liberia [press release]. Disease Outbreak News. World Health Organization; March 30, 2014.
9. Ebola virus disease, West Africa-update [press release]. Disease Outbreak News. Guinea, Africa; World Health Organization; May 24, 2014.
10. Towner JS, et al. Rapid diagnosis of Ebola hem-orrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78(8):4330-4341.
11. Schoepp RJ, Rossi CA, Khan SH, Goba A, Fair JN. Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerg Infect Dis. 2014;20(7):1176-1182.
12. Becquart P, et al. High prevalence of both humoral and cellular immunity to Zaire ebolavi-rus among rural populations in Gabon. PLoS One. 2010;5(2):e9126.
13. Boisen ML, et al., Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filovi-ruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol. 2015;28(1):19-31.
14. Leroy EM, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000;355(9222):2210-2215.
15. Tong YG, et al. Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone. Nature. 2015;524(7563):93-96.
16. Olabode AS, Jiang X, Robertson DL, Lovell SC. Ebolavirus is evolving but not changing: no evidence for functional change in EBOV from 1976 to the 2014 outbreak. Virology. 2015;482:202-207.
17. Grolla A, Mehedi M, Lindsay R, Bosio C, Duse A, Feldmann H. Enhanced detection of Rift Valley fever virus using molecular assays on whole blood samples. J Clin Virol. 2012;54(4):313-317.
18. Demby AH, Chamberlain J, Brown DW, Clegg CS. Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol. 1994;32(12):2898-2903.
19. Lee MA, et al. Real-time fluorescence-based PCR for detection of malaria parasites. J Clin Microbiol. 2002;40(11):4343-4345.
20. Dreier J, Störmer M, Kleesiek K. Use of bacterio-phage MS2 as an internal control in viral reverse transcription-PCR assays. J Clin Microbiol. 2005;43(9):4551-4557.
21. Medecins Sans Frontieres. MSF Ethics Review Board Standard Operating Procedures. MSF Web site. http://fieldresearch.msf.org/msf/handle/10144/294968. Updated February 12, 2013. Accessed October 5, 2015.